Ani Pharmaceuticals (ANIP) Income from Continuing Operations (2011 - 2026)

Ani Pharmaceuticals has disclosed Income from Continuing Operations across 16 years of filings, most recently posting $24.7 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations rose 189.7% year-over-year to $24.7 million; the TTM figure through Jun 2026 stood at $108.3 million (up 1158.17% YoY), while the FY2025 annual figure was $78.3 million, up 522.94% from the prior year.
• Income from Continuing Operations came in at $24.7 million for Q2 2026 at Ani Pharmaceuticals, down from $29.5 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $29.5 million in Q1 2026 to a low of -$24.2 million in Q3 2024.
• Average Income from Continuing Operations over 5 years is $4.7 million, with a median of $3.9 million recorded in 2023.
• Year-over-year, Income from Continuing Operations plunged 18372.73% in 2022 and soared 1135.21% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$4.3 million in 2022, then soared by 127.12% to $1.2 million in 2023, then plunged by 989.7% to -$10.3 million in 2024, then jumped by 367.86% to $27.5 million in 2025, then fell by 10.27% to $24.7 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were $24.7 million in Q2 2026, $29.5 million in Q1 2026, and $27.5 million in Q4 2025.